Outlook on the Future of Ovarian and Other Gynecologic Cancers
Maurie Markman, MD, President of Medicine and Science at the Cancer Treatment Centers of America, discusses where he sees the field of ovarian cancer and other gynecologic cancers headed in the future, based on the research shared at the 2018 ASCO Annual Meeting.
Maurie Markman, MD, President of Medicine and Science at the Cancer Treatment Centers of America, discusses where he sees the field of ovarian cancer and other gynecologic cancers headed in the future, based on the research shared at the 2018 ASCO Annual Meeting.
Markman says the focus now is on targeted therapies, precision medicine, and immunotherapy. When he completed his own medical training years ago, he went right to the National Cancer Institute to the Laboratory of Tumor Immunology and Biology because he believed the immune system would play a vital role in cancer research. However, he was still a few decades ahead of his time.
Now it is evident that the immune system plays a significant role in controlling and potentially curing cancers, Markman says. With the use of checkpoint inhibitors, immune modulators, and CAR T cells, research is now just beginning to understand the complex role of the immune system.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
